Provided by Tiger Fintech (Singapore) Pte. Ltd.

Liquidia Technologies Inc

12.19
+0.13001.08%
Post-market: 12.300.1100+0.90%16:23 EDT
Volume:1.03M
Turnover:12.46M
Market Cap:1.04B
PE:-7.13
High:12.30
Open:12.10
Low:11.89
Close:12.06
Loading ...

Company Profile

Company Name:
Liquidia Technologies Inc
Exchange:
NASDAQ
Establishment Date:
2004
Employees:
170
Office Location:
419 Davis Drive,Suite 100,Morrisville,North Carolina,United States
Zip Code:
27560
Fax:
919 328 4402
Introduction:
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Directors

Name
Position
Roger A. Jeffs
Director and Chief Executive Officer
Stephen Bloch
Chairperson of the Board and Director
Arthur Kirsch
Director
Damian deGoa
Director
David Johnson
Director
Joanna Horobin
Director
Katie Rielly Gauvin
Director
Paul B. Manning
Director
Raman Singh
Director

Shareholders

Name
Position
Roger A. Jeffs
Director and Chief Executive Officer
Michael Kaseta
Chief Operating Officer and Chief Financial Officer
Dana Boyle
Chief Accounting Officer
Jason Adair
Chief Business Officer
Rajeev Saggar
Chief Medical Officer
Russell Schundler
General Counsel and Secretary
Scott Moomaw
Chief Commercial Officer